SEC 13F Intelligence

Managers / Q3 2019 · view latest →

Consonance Capital Management LP

CIK 0001544773 · 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK, NY, 10019 · 212.660-8062

Reported Value
$1.0B
Q3 2019
Positions
30
Filings on Record
15
2019–present window
Filed
Nov 14, 2019
original filing

Summary

Consonance Capital Management LP reported $1.0B in U.S.-listed holdings across 30 positions for Q3 2019.

Its largest position, Amarin, represents 9.6% of the portfolio.

Compared with Q2 2019, the fund opened 7 new positions and exited 7.

Portfolio Metrics

Turnover
+28.3%
vs prior filed quarter
Top-10 Concentration
+65.7%
share of reported value
Largest Position
+9.6%
Amarin
New / Exited
7 / 7
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $1.6BQ1 ’19Q2 ’19: $1.4BQ3 ’19: $1.0BQ3 ’19Q4 ’19: $1.6BQ1 ’20: $1.3BQ1 ’20Q2 ’20: $1.7BQ3 ’20: $821MQ3 ’20Q4 ’20: $1.1BQ1 ’21: $938MQ1 ’21Q2 ’21: $831MQ3 ’21: $183MQ3 ’21Q4 ’21: $153MQ1 ’22: $59MQ1 ’22Q2 ’22: $24MQ3 ’22: $7MQ3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 86.9%Other: 13.1%
  • Common Stock · 86.9% · $878M
  • Other · 13.1% · $133M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
GMEDGLOBUS MED INCNEW+1.31M1.31M+$67M$67M
TNDMTANDEM DIABETES CARE INCNEW+1.02M1.02M+$60M$60M
ALGNALIGN TECHNOLOGY INCNEW+299.0K299.0K+$54M$54M
PODDINSULET CORPNEW+155.8K155.8K+$26M$26M
CDNACAREDX INCNEW+726.1K726.1K+$16M$16M
SRPTSAREPTA THERAPEUTICS INCNEW+12.0K12.0K+$904,000$904,000
INTRA CELLULAR THERAPIES INCNEW+20.0K20.0K+$149,000$149,000
ARQULE INCADDED+3.96M4.01M+$28M$29M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2019

30 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1AMARIN CORP PLCSPONS ADR NEW9.59%$97M6.39M
2CN2CATALYST PHARMACEUTICALS INChistory →COM9.39%$95M17.88M
3UTHRUNITED THERAPEUTICS CORP DELhistory →COM7.64%$77M967.6K
4GMEDGLOBUS MED INChistory →CL A6.64%$67M1.31M
5TNDMTANDEM DIABETES CARE INChistory →COM NEW5.97%$60M1.02M
6QUREUNIQURE NVhistory →SHS5.56%$56M1.43M
7KARYOPHARM THERAPEUTICS INCCOM5.56%$56M5.84M
8VCELVERICEL CORPhistory →COM5.46%$55M3.64M
9ALGNALIGN TECHNOLOGY INChistory →COM5.35%$54M299.0K
10OMEROMEROS CORPhistory →COM4.57%$46M2.83M
11EPIZYME INCCOM4.06%$41M3.98M
12OXFORD IMMUNOTEC GLOBAL PLCORD SHS3.53%$36M2.14M
13STAASTAAR SURGICAL COhistory →COM PAR $0.013.13%$32M1.23M
14IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM3.02%$31M1.68M
15ARQULE INCCOM2.85%$29M4.01M
16KDMNKADMON HLDGS INChistory →COM2.67%$27M10.69M
17RETROPHIN INCCOM2.65%$27M2.31M
18PODDINSULET CORPhistory →COM2.54%$26M155.8K
19ADMAADMA BIOLOGICS INChistory →COM2.25%$23M5.11M
20CDNACAREDX INChistory →COM1.62%$16M726.1K
21AUPHAURINIA PHARMACEUTICALS INChistory →COM1.35%$14M2.56M
22CHEMOCENTRYX INCCOM1.12%$11M1.67M
23ANIPANI PHARMACEUTICALS INChistory →COM1.03%$10M142.9K
24MUSTANG BIO INCCOM1.02%$10M3.16M
25KRYSKRYSTAL BIOTECH INCCOM0.77%$8M224.1K
26SVRASAVARA INCCOM0.41%$4M1.57M
27SRPTSAREPTA THERAPEUTICS INCCOM0.09%$904,00012.0K
28HOMOLOGY MEDICINES INCCOM0.07%$734,00040.6K
29IMMUIMMUNOMEDICS INCCOM0.06%$597,00045.0K
30INTRA CELLULAR THERAPIES INCCOM0.01%$149,00020.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$7M2Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$24M7Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$59M8May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$153M15Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$183M17Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$831M32Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$938M35May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.1B38Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$821M27Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.7B32Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.3B31May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.6B35Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.0B30Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.4B30Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.6B26May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.